New Men B immunisation advice

Following recent high profile stories about child deaths from meningitis B, Public Health England has issued further advice:

Men B immunisation programme

Following recent media coverage about the death of a young girl from invasive meningococcal disease caused by Men B, many GP practices have had queries from parents about the availability of Men B immunisation. 

This information is taken from Public Health England publications and the GOV.UK website (see below for details).

What is the national policy for Men B immunisation?

The Men B immunisation programme started on 1 September 2015 for babies aged 2 months, ie, babies born on or after 1 July 2015.  There was a limited catch-up programme for babies born on or after 1 May 2015.  The routine schedule is for immunisation to be given at 2 and 4 months with the primaries, with a booster at 12 months.

Can I vaccinate children born before 1 May 2015 if parents request it? 

No. The national stock of Bexsero® should only be used to vaccinate children who are eligible for NHS vaccination.

Can I vaccinate children born on or after 1 May 2015 who have not yet been vaccinated?

Yes.  All children in the eligible cohort (ie, born on or after 1 May 2015) remain eligible for Men B immunisation until the age of two years. When Bexsero® has not been given as part of a primary course, give two doses at least two months apart. Those children who have received one dose before their first birthday only require one more dose. Please see the MenB PGD for more information.

If parents ask to pay for Men B immunisation for their children, what should I tell them?

GPs should not charge their own patients (ie, those registered at their practice) a private fee for the vaccine.

Parents seeking the vaccine privately should be made aware that they will be liable for the full costs of the vaccine and any additional administration charges that the private provider may apply. We understand that GSK has supply constraints on the Bexsero vaccine for the private market. Practices must not use centrally-procured stock for the national programme to vaccinate private patients or any patients outside the eligible cohort (other than those at high risk as defined in the green book).

Further information

Last updated : 16 Mar 2016

 

Covid-19 vaccination campaign – January update (27 Jan 2021)

Since our last newsletter there have been a number of developments with the Covid vaccination campaign, most notably: The approval of the Oxford/AstraZeneca vaccine, NHS England’s instruction to prioritise essential...
Read more »

Hesitancy around Covid vaccination (27 Jan 2021)

A poll carried out by the Royal Society for Public Health in December found that just 57% of respondents from black or ethnic minority backgrounds were likely to accept...
Read more »

Helping sessional GPs to match to practices in their area during the Covid-19 vaccination programme (06 Jan 2021)

During these difficult times we appreciate that general practice is under extreme workload pressures trying to meet numerous demands which they may be struggling to do so with existing staff...
Read more »

Integrated Care Systems legal structure proposals consultation (16 Dec 2020)

A new NHS England report seeking views on proposals to create a new legal structure for ICS was published recently, setting out plans to place ICS on a statutory footing...
Read more »

December 2020 workforce survey – thank you for responding (15 Dec 2020)

Our latest workforce survey officially closed on Monday 14 December, thank you to those who took the time to provide us with this valuable information, particularly at the moment when everyone working...
Read more »

New Covid-19 vaccination ES guidance (14 Dec 2020)

In the first two weeks of December 2020, we published three new documents to support practices who have signed-up to deliver the Covid-19 Vaccination Programme Enhanced Service (ES). Medicolegal matters...
Read more »
Next Page »
« Previous Page